State of the biotech sector—2007 - p728

Stacy Lawrence

doi:10.1038/nbt0708-728

Full Text - State of the biotech sector—2007 | PDF (233 KB) - State of the biotech sector—2007

Poised to branch out - pp729 - 732

Vivien Marx

doi:10.1038/nbt0708-729

Although dendrimers have not yet taken the drug industry by storm, biomedical research and industrial applications of these tiny, highly branched molecules continue to grow. Vivien Marx reports.

Abstract - | Full Text - Poised to branch out | PDF (172 KB) - Poised to branch out

Preparing for (and avoiding) the courtroom - pp733 - 735

Jeff Wolfson & Russ Emerson

doi:10.1038/bioe.2008.6

PDF (121 KB) - Preparing for (and avoiding) the courtroom

Europe to ban direct-to-consumer genetic tests? - pp736 - 737

Pascal Borry

doi:10.1038/nbt0708-736

Full Text - Europe to ban direct-to-consumer genetic tests? | PDF (203 KB) - Europe to ban direct-to-consumer genetic tests?

Dichotomies between computational and mathematical models - pp737 - 738

C Anthony Hunt, Glen E P Ropella, Sunwoo Park & Jesse Engelberg

doi:10.1038/nbt0708-737

Full Text - Dichotomies between computational and mathematical models | PDF (145 KB) - Dichotomies between computational and mathematical models

Reply to Dichotomies between computational and mathematical models - pp738 - 739

doi:10.1038/nbt0708-738

Full Text - Reply to Dichotomies between computational and mathematical models | PDF (162 KB) - Reply to Dichotomies between computational and mathematical models

HLA-haplotype banking and iPS cells - pp739 - 740

Norio Nakatsuji, Fumiaki Nakajima & Katsushi Tokunaga

doi:10.1038/nbt0708-739

Full Text - HLA-haplotype banking and iPS cells | PDF (238 KB) - HLA-haplotype banking and iPS cells

Global mRNA changes in microarray experiments - pp741 - 742

Matthew A Hannah, Henning Redestig, Andrea Leisse & Lothar Willmitzer

doi:10.1038/nbt0708-741

Full Text - Global mRNA changes in microarray experiments | PDF (220 KB) - Global mRNA changes in microarray experiments | Supplementary information

(Re)defining biopharmaceutical - pp743 - 751

Ronald A Rader

doi:10.1038/nbt0708-743

Vested interests are redefining, rebranding and co-opting what is 'biopharmaceutical'. This is not just a matter of semantics—the core identity of the biotech industry and its products is at stake.

Abstract - | Full Text - (Re)defining biopharmaceutical | PDF (280 KB) - (Re)defining biopharmaceutical

How many patents does a biopharmaceutical company need? - pp763 - 766

Deepak Kumar Parida, Ritu Mehdiratta & Gayatri Saberwal

doi:10.1038/nbt0708-763

Young biotech companies may not need extensive patent portfolios to survive or grow.

Abstract - | Full Text - How many patents does a biopharmaceutical company need? | PDF (304 KB) - How many patents does a biopharmaceutical company need? | Supplementary information

Recent patent applications in mass spectrometry - p767

doi:10.1038/nbt0708-767

Full Text - Recent patent applications in mass spectrometry | PDF (53 KB) - Recent patent applications in mass spectrometry

A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysis - pp779 - 785

Thomas A Down, Vardhman K Rakyan, Daniel J Turner, Paul Flicek, Heng Li, Eugene Kulesha, Stefan Gräf, Nathan Johnson, Javier Herrero, Eleni M Tomazou, Natalie P Thorne, Liselotte Bäckdahl, Marlis Herberth, Kevin L Howe, David K Jackson, Marcos M Miretti, John C Marioni, Ewan Birney, Tim J P Hubbard, Richard Durbin, Simon Tavaré & Stephan Beck

doi:10.1038/nbt1414

An inability to estimate absolute DNA methylation levels has slowed progress in understanding the role of this epigenetic modification in health and disease. Down et al. describe an algorithm for analyzing methylated DNA immunoprecipitation profiles generated using either high-throughput sequencing or oligonucleotide arrays.

Abstract - | Full Text - A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysis | PDF (984 KB) - A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysis | Supplementary information

Refinement and standardization of synthetic biological parts and devices - pp787 - 793

Barry Canton, Anna Labno & Drew Endy

doi:10.1038/nbt1413

Abstract - | Full Text - Refinement and standardization of synthetic biological parts and devices | PDF (1,035 KB) - Refinement and standardization of synthetic biological parts and devices | Supplementary information

See also: News and Views by Arkin

Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds - pp795 - 797

Danwei Huangfu, René Maehr, Wenjun Guo, Astrid Eijkelenboom, Melinda Snitow, Alice E Chen & Douglas A Melton

doi:10.1038/nbt1418

Existing methods for reprogramming somatic cells to 'induced pluripotent stem cells' are inefficient, with only a small fraction of the starting cell population becoming pluripotent. Working with mouse embryonic fibroblasts, Hunagfu et al. increase reprogramming efficiency by treatment with DNA methyltransferase and histone deacetylase inhibitors.

First Paragraph - | Full Text - Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds | PDF (346 KB) - Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds | Supplementary information

An orally delivered small-molecule formulation with antiangiogenic and anticancer activity - pp799 - 807

Ofra Benny, Ofer Fainaru, Avner Adini, Flavia Cassiola, Lauren Bazinet, Irit Adini, Elke Pravda, Yaakov Nahmias, Samir Koirala, Gabriel Corfas, Robert J D'Amato & Judah Folkman

doi:10.1038/nbt1415

Widespread use of antiangiogenic drugs for cancer therapy is limited in part by the requirement for intravenous injection. Benny et al. describe an oral formulation of an antiangiogenic small molecule that inhibits tumor growth and prevents liver metastases in mice.

Abstract - | Full Text - An orally delivered small-molecule formulation with antiangiogenic and anticancer activity | PDF (671 KB) - An orally delivered small-molecule formulation with antiangiogenic and anticancer activity

See also: News and Views by James et al.

Establishment of HIV-1 resistance in CD4⁺ T cells by genome editing using zinc-finger nucleases - pp808 - 816

Elena E Perez, Jianbin Wang, Jeffrey C Miller, Yann Jouvenot, Kenneth A Kim, Olga Liu, Nathaniel Wang, Gary Lee, Victor V Bartsevich, Ya-Li Lee, Dmitry Y Guschin, Igor Rupniewski, Adam J Waite, Carmine Carpenito, Richard G Carroll, Jordan S Orange, Fyodor D Urnov, Edward J Rebar, Dale Ando, Philip D Gregory, James L Riley, Michael C Holmes & Carl H June

doi:10.1038/nbt1410

Abstract - | Full Text - Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases | PDF (1,483 KB) - Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases | Supplementary information

Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1 - pp817 - 823

Yukihiko Aikawa, Kimiko Morimoto, Tetsuya Yamamoto, Hisaaki Chaki, Akira Hashiramoto, Hirokazu Narita, Shuichi Hirono & Shunichi Shiozawa

doi:10.1038/nbt1412

Therapies that target only one inflammatory cytokine such as tumor necrosis factor are often insufficient to treat rheumatoid arthritis. Aikawa et al. show that a small molecule targeting c-Fos/AP-1, a transcription factor that regulates both inflammatory cytokines and matrix metalloproteinases, inhibits type II collagen-induced arthritis in mice.

Abstract - | Full Text - Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1 | PDF (589 KB) - Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1 | Supplementary information

Electrostatic readout of DNA microarrays with charged microspheres - pp825 - 830

Nathan G Clack, Khalid Salaita & Jay T Groves

doi:10.1038/nbt1416

Microarray platforms usually rely on fluorescence detection. Clack et al. present an equally sensitive, label-free technique that electrostatically detects DNA or RNA hybridization after randomly dispersing charged microspheres onto the microarray surface.

First Paragraph - | Full Text - Electrostatic readout of DNA microarrays with charged microspheres | PDF (583 KB) - Electrostatic readout of DNA microarrays with charged microspheres | Supplementary information

A walk through the Valley of Death - pp833 - 834

Mari Paul

doi:10.1038/nbt0708-833

Expert tips for acquirers and acquirees to get through a difficult post-merger integration.

Abstract - | Full Text - A walk through the Valley of Death | PDF (152 KB) - A walk through the Valley of Death

People - p836

doi:10.1038/nbt0708-836

Full Text - People | PDF (91 KB) - People